Overall, for the first time, the results of this study suggested that STON2 is upregulated in ovarian cancer and its expression is correlated with intraperitoneal metastasis, intestinal metastasis, intraperitoneal recurrence, ascites with tumor cells, CA153 level, and poor prognosis in EOC patients. The gene discussed is STON2; the disease is ovarian carcinoma.